• Oxford Biomedica to license LentiVector to Juno pharmatimes
    March 19, 2020
    Oxford Biomedica has signed a Licence and Clinical Supply Agreement (LSA) with Bristol-Myers Squibb’s Juno Theraputics, granting the latter a non-exclusive license to the LentiVector platform.
PharmaSources Customer Service